GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (STU:6LJ) » Definitions » 3-Year EPS without NRI Growth Rate

Matinas BioPharma Holdings (STU:6LJ) 3-Year EPS without NRI Growth Rate : 3.60% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Matinas BioPharma Holdings 3-Year EPS without NRI Growth Rate?

Matinas BioPharma Holdings's EPS without NRI for the three months ended in Mar. 2024 was €-0.03.

During the past 3 years, the average EPS without NRI Growth Rate was 3.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Matinas BioPharma Holdings was 30.20% per year. The lowest was -24.20% per year. And the median was 6.80% per year.


Competitive Comparison of Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate falls into.



Matinas BioPharma Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Matinas BioPharma Holdings  (STU:6LJ) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Matinas BioPharma Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (STU:6LJ) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Matinas BioPharma Holdings (STU:6LJ) Headlines

No Headlines